CD36: a key mediator of resistance to HER2 inhibitors in breast cancer.
- Resource Type
- Opinion
- Authors
- Feng, William W.; Bang, Scott; Kurokawa, Manabu
- Source
- Molecular & Cellular Oncology. Mar2020, Vol. 7 Issue 2, p1-3. 3p.
- Subject
- *BREAST cancer
*LAPATINIB
*TRASTUZUMAB
*LIPID metabolism
*DRUG resistance in cancer cells
- Language
- ISSN
- 2372-3556
Acquired resistance to anti-HER2 therapy is a significant clinical challenge in breast cancer. We recently discovered that during acquisition of resistance to HER2 inhibition, upregulation of the fatty acid transporter CD36 takes place, playing a key role in metabolic rewiring and resistance to anti-HER2 therapy. [ABSTRACT FROM AUTHOR]